Perspective Therapeutics(CATX) - 2022 Q4 - Annual Report

Table of Contents United States Securities and Exchange Commission WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission File No. 001-33407 Isoray, Inc. (Exact name of registrant as specified in its charter) Delaware 41-1458152 (State of incorpo ...